The evolving science of apolipoprotein-L1 and kidney disease

Purpose of reviewThere are evolving epidemiological and biological data to support an association between the gene encoding apolipoprotein-L1 (APOL1) and progressive chronic kidney disease (CKD) among African-Americans. Recent findingsIndividuals with two APOL1 risk alleles are at greater risk of incident albuminuria, CKD, and progression to end-stage renal disease despite optimal blood pressure management and use of angiotensin-converting enzyme inhibitors. These variants also appear to influence outcomes in donor and recipients in kidney transplantation. Recent studies have also variably shown a potential role of APOL1 variants in cardiovascular disease. A number of studies have addressed genetic and environmental factors such as HIV but most do not modify the course of APOL1-related kidney disease. Although the exact mechanism remains unclear, functional studies have demonstrated the effect of APOL1 and related protein on innate immunity and cytotoxicity. SummaryAPOL1 is an important genetic risk factor for kidney disease among African-Americans. With approximately one in 10 African-Americans at risk, further studies are warranted to identify underlying biological mechanisms and other potential modifiers leading to CKD. Moreover, studies that clarify the association of APOL1 variants with cardiovascular disease, independent of CKD, are also needed.

[1]  Nicholette D. Palmer,et al.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Catherine C. Robertson,et al.  Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. , 2016, Journal of the American Society of Nephrology : JASN.

[3]  M. Fornage,et al.  APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline. , 2016, Journal of the American Society of Nephrology : JASN.

[4]  Nicholette D. Palmer,et al.  APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors , 2016, Transplantation.

[5]  B. Astor,et al.  Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[6]  C. Winkler,et al.  APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults: An Autopsy Study. , 2015, Journal of the American Society of Nephrology : JASN.

[7]  Mardge H. Cohen,et al.  APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  Nicholette D. Palmer,et al.  Apolipoprotein L1 Gene Variants in Deceased Organ Donors Are Associated With Renal Allograft Failure , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  C. Rotimi,et al.  APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans , 2015, BMC Genomics.

[10]  M. Fornage,et al.  Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[11]  G. Genovese,et al.  Copy Number Variation at the APOL1 Locus , 2015, PloS one.

[12]  M. Ramsay,et al.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. , 2015, Journal of the American Society of Nephrology : JASN.

[13]  Patrick D. Dummer,et al.  APOL1 Toxin, Innate Immunity and Kidney Injury , 2015, Kidney international.

[14]  Nicholette D. Palmer,et al.  Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation , 2015, Kidney international.

[15]  A. Zonderman,et al.  Apolipoprotein L1, income and early kidney damage , 2015, BMC Nephrology.

[16]  B. Freedman,et al.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. , 2015, Journal of the American Society of Nephrology.

[17]  C. Winkler,et al.  Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. , 2015, Journal of the American Society of Nephrology : JASN.

[18]  A. Reiner,et al.  Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. , 2014, JAMA.

[19]  Steven Wolinsky,et al.  The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Winkler,et al.  APOL1 kidney risk alleles: population genetics and disease associations. , 2014, Advances in chronic kidney disease.

[21]  K. Skorecki,et al.  APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. , 2014, American journal of physiology. Renal physiology.

[22]  V. D’Agati,et al.  Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1 , 2014, Kidney international.

[23]  M. Rocco,et al.  Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial , 2014, Kidney international.

[24]  Nicholette D. Palmer,et al.  APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes , 2014, Kidney international.

[25]  O. Gribouval,et al.  APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  A. Pereira,et al.  MYH9 and APOL1 Gene Polymorphisms and the Risk of CKD in Patients with Lupus Nephritis from an Admixture Population , 2014, PloS one.

[27]  Nicholette D. Palmer,et al.  Gene-gene interactions in APOL1-associated nephropathy. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  S. Gabriel,et al.  Increased Burden of Cardiovascular Disease in Carriers of APOL1 Genetic Variants , 2014, Circulation research.

[29]  Mei-Cheng Wang,et al.  Risk of end-stage renal disease following live kidney donation. , 2014, JAMA.

[30]  John D Reveille,et al.  End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 , 2014, Arthritis & rheumatology.

[31]  Barry I. Freedman,et al.  APOL1 risk variants, race, and progression of chronic kidney disease. , 2013, The New England journal of medicine.

[32]  M. Fornage,et al.  APOL1 variants associate with increased risk of CKD among African Americans. , 2013, Journal of the American Society of Nephrology : JASN.

[33]  M. Rocco,et al.  JC polyoma virus interacts with APOL1 in African Americans with non-diabetic nephropathy , 2013, Kidney international.

[34]  M. Beggs,et al.  Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. , 2013, Journal of the American Society of Nephrology : JASN.

[35]  Ashish,et al.  APOL1 Null Alleles from a Rural Village in India Do Not Correlate with Glomerulosclerosis , 2012, PloS one.

[36]  G. Genovese,et al.  The APOL1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5‐Year Allograft Survival , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  B. Astor,et al.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans , 2012, Kidney international.

[38]  C. Winkler,et al.  HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathologic characteristics , 2012, Kidney international.

[39]  V. D’Agati,et al.  APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[40]  A. Ashley-Koch,et al.  MYH9 and APOL1 are both associated with sickle cell disease nephropathy , 2011, British Journal of Haematology.

[41]  M. Rocco,et al.  Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  J. O'Toole,et al.  APOL1 localization in normal kidney and nondiabetic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[43]  Giulio Genovese,et al.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[44]  C. Young,et al.  Ethnic and Gender Related Differences in the Risk of End‐Stage Renal Disease After Living Kidney Donation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[45]  A. Köttgen,et al.  The MYH9/APOL1 region and chronic kidney disease in European-Americans. , 2011, Human molecular genetics.

[46]  M. Rocco,et al.  The APOL1 Gene and Allograft Survival after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  M. Schnitzler,et al.  Racial variation in medical outcomes among living kidney donors. , 2010, The New England journal of medicine.

[48]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[49]  S. Rosset,et al.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene , 2010, Human Genetics.

[50]  M. Lisanti,et al.  Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. , 2010, American journal of physiology. Renal physiology.

[51]  N. Perico,et al.  ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. , 2009, Journal of the American Society of Nephrology : JASN.

[52]  Zeyu Jiang,et al.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death , 2008, Autophagy.

[53]  D. Reich,et al.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans , 2008, Nature Genetics.

[54]  D. Vlahov,et al.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis , 2008, Nature Genetics.

[55]  D. Fine,et al.  Antiretroviral therapy in the treatment of HIV-associated nephropathy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[56]  E. Meydrech,et al.  Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. , 1992, The New England journal of medicine.

[57]  V. D’Agati,et al.  Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. , 1989, Kidney international.

[58]  Barry I Freedman,et al.  Histopathologic findings associated with APOL1 risk variants in chronic kidney disease , 2015, Modern Pathology.

[59]  B. Leea,et al.  The APOL 1 Genotype of African American Kidney Transplant Recipients Does Not Impact 5-Year Allograft Survival , 2012 .

[60]  J. Bartlett,et al.  Dual HIV-1 infection associated with rapid disease progression , 2004 .

[61]  Jinlai Liu,et al.  Systolic Blood Pressure Intervention Trial (SPRINT) , 2013 .